Ilaris® (canakinumab) – New indication
August 25, 2023 - The FDA approved Novartis’ Ilaris (canakinumab), for the symptomatic treatment of adult patients with gout flares in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
Top